Press release from Artimplant´s Nominating Committee

Press release from Artimplant´s Nominating Committee

In advance of Artimplant's Annual Meeting of Stockholders on May 3, 2007, Artimplant's Nominating Committee has decided to propose that Ingemar Kihlström, Lennart Ribohn and Dick Söderberg be re-elected as members of the Board of Directors. Birgit Stattin-Norinder declines re-election. The Nominating Committee has also decided to propose Anna Malm Bernsten, currently deputy board member, and Wenche Rolfsen as new members.

Wenche Rolfsen, 54, is Vice President, Phase I Europe, Quintiles and Managing Director of Quintiles AB a contract research organization with core business in clinical development of drugs. She has among others, Board assignments for Biovitrum AB and Uppsala University Holding AB.

For additional information, please contact:
Ingemar Kihlström, Chairman, phone +46 733-82 11 02
Web site: www.artimplant.com


About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as dental applications.

Artimplant is a public company listed on the Nordic Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.